



PRESS RELEASE

ENYO Pharma opens a new subsidiary in Australia as a new managing center for clinical trials

Lyon, October 26, 2017. ENYO Pharma, a biopharmaceutical company developing new molecules with an innovative approach inspired by viruses, made a strategic decision and has recently decided to open its first wholly owned subsidiary in Melbourne, Australia, because of its excellent clinical trials development capabilities and attractive conditions offered by the government. The Australian Government is very supportive of biotech startups and the Victorian Government Business Office provides good business development networking. This office will be the new ENYO Pharma center to manage EYP001 (an FXR agonist) clinical trials in the Asia-Pacific region for chronic Hepatitis B. A Phase 1b study of EYP001 is currently submitted in 4 countries and two new Australian centers in Sydney and Perth have joined the study and started recruitment.

ENYO Pharma bases its innovation on mimicking viral strategies to discover new cellular targets and is currently developing drug candidates in therapeutic areas such as infectious and metabolic diseases. One of the company's leading programs is a new drug EYP001, against chronic Hepatitis B which is a major public health concern in the Asia-Pacific region. More than a half of the global population infected worldwide by Hepatitis B are located in this region, representing 129 million patients.

"ENYO Pharma is currently looking forward to working in this region as the well-established clinical expertise in this part of the world adds important value to ENYO Pharma R&D efforts and specifically our expeditious development of EYP001" commented Pietro Scalfaro, M.D., Chief Medical Officer of ENYO Pharma SA.

"Melbourne's strong biotechnology sector is the leading research and clinical trial hub in the Asia Pacific region. ENYO Pharma is a leading biotechnology innovator in infectious diseases and the Government of Victoria is proud to welcome their new research subsidiary into Melbourne, Australia." said the Minister for Innovation and Trade, Minister Philip Dalidakis.

ENYO Pharma's technology and pipeline - <http://www.enyopharma.com/science/principle/>

ENYO Pharma SA - www.enyopharma.com

Contact ENYO Pharma

Jacky Vonderscher

contact@enyopharma.com - +33 (0)4 37 70 02 19

Press contact: NewCap Media

Annie-Florence Loyer

afloyer@newcap.fr – +33 (0)1 44 71 00 12/ +33 (0)6 88 20 35 59